New combo injection aims to soothe arthritic knees

NCT ID NCT07323342

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether injecting a mix of hyaluronic acid and fibrinogen into the knee can reduce pain and improve function in people with knee osteoarthritis. About 31 adults aged 45 to 75 will receive the injection as part of routine care. Researchers will track changes in pain, stiffness, and daily activity over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

hyaluronic acid combined with fibrinogen

What this could lead to

If it works, this could offer a new option for easing knee osteoarthritis pain and improving mobility.

What could go wrong

This is a very small, early study with no comparison group, so results may not be reliable or apply to everyone. The treatment is already used, so major breakthroughs are unlikely.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KNEE OSTEOARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

agnosia osteoarthritis, knee

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Xuong Khop Viet clinic

    RECRUITING

    Ho Chi Minh City, 700000, Vietnam

    Contact Phone: •••-•••-•••• Email: •••••@•••••